Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients | ||
| Egyptian Journal of Pure and Applied Science | ||
| Article 5, Volume 60, Issue 1, January 2022, Pages 73-84 PDF (746.1 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejaps.2022.125337.1026 | ||
| Authors | ||
| Hiam Salem* 1; Nadia Y. S. Morcos1; Wahid Doss2; Mohamed Makhlouf3; Kamal El Atrebi4; Eman Saleh1 | ||
| 1Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt | ||
| 2Tropical Medicine and Hepatology Department, Faculty of Medicine, Cairo university, Giza, Egypt | ||
| 3Internal Medicine Department, Faculty of Medicine, Ain shams university, Cairo, Egypt | ||
| 4National Hepatology and Tropical Medicine Research Institute, Egypt | ||
| Abstract | ||
| Even though Sofosbuvir (SOF) has revolutionized the treatment of chronicHCV infection, treatment with pegylated interferon in combination with Ribavirin isconsidered the standard of care for treatment in many countries. Aim: This study aimedto monitor the efficacy and safety of SOF/RBV with or without Peg-INF-α-2a, inEgyptian patients with chronic HCV genotype 4. Subjects: 165 patients infected withHCV-GT4 were enrolled in this prospective study. Eligible patients received therecommended doses of SOF/RBV for 24 weeks (Dual treatment) or SOF/RBV/Peg-IFN-α-2a for 12 weeks (Triple treatment). All patients were followed up for 24 weeks afterthe end of therapy. Results: The highest SVR24 rates were attained with the Triple groupcorresponding to the Dual group. Patients who failed to treatment, had higher baselinePDGF in both groups, TNF-α in the Dual group, and lower TSH in the Triple group.Adverse effects included a decrease in hemoglobin and WBCs with an increase increatinine, ferritin and TSH. The favorable effects included normalization of liverindices, correction of hypolipidemia, together with a decrease in TNF-α. Moreover, thecurrent study showed the overall frequency of IL28B genotypes was 100% for genotypeCT. Results: Results of SOF-based therapies achieved better SVR24 rates with theaddition of Peg-INF-α-2a. | ||
| Keywords | ||
| HCV; Sofosbuvir; Interferon; Ribavirin; SVR | ||
|
Statistics Article View: 306 PDF Download: 237 |
||
